Stabilitech is a groundbreaking brand at the forefront of the future of immunization. With a focus on oral vaccines, they are revolutionizing the way vaccines are delivered, administered, and distributed. Stabilitech's patented OraPro technology allows for the safe and effective delivery of vaccines through tablets, capsules, or nasal sprays, making it easier for individuals to self-administer and eliminating the need for healthcare professionals.

The advantages of Stabilitech's oral vaccine technology are remarkable. It offers a faster and more convenient vaccination process, as doses can be directly posted to patients' doors. This approach also ensures a safer experience, as it minimizes contact with healthcare staff and reduces the spread of infectious diseases.

Additionally, the cost savings are significant, as no clinics or cold chain requirements are necessary. Stabilitech's OraPro technology works by leveraging the body's own cells to produce proteins that induce immunity or provide novel therapies. Its thermostability technology allows the viral vector to survive the body's temperatures, ensuring its effectiveness.

This innovative platform can be used for various diseases, including respiratory, intestinal, or systemic viruses. One of Stabilitech's notable initiatives is the development of the OraPro-Covid-19 vaccine. This thermally stable oral vaccine aims to tackle the challenges posed by injectable vaccines, such as supply chain and logistical issues.

With the ability to be sent by post and self-administered at home, the OraPro-Covid-19 vaccine offers a promising solution to combat the ongoing coronavirus pandemic. Stabilitech's mission is to democratize vaccines, ensuring that immunization is accessible to all, particularly in developing countries where current vaccine technology limitations prevail. By providing a reliable and efficient delivery system for vaccines, Stabilitech is working towards saving lives and improving global health